
June 23 (Reuters) - Corcept Therapeutics Inc CORT.O:
CORCEPT PRESENTS DATA FROM TREATMENT PHASE OF CATALYST TRIAL AT AMERICAN DIABETES ASSOCIATION’S 85TH SCIENTIFIC SESSIONS WITH SIMULTANEOUS PUBLICATION IN DIABETES CARE
CORCEPT THERAPEUTICS INC - CATALYST TRIAL MEETS PRIMARY ENDPOINT WITH SIGNIFICANT IMPROVEMENT IN HBA1C
CORCEPT THERAPEUTICS INC - CATALYST TRIAL MEETS SECONDARY ENDPOINTS WITH REDUCED BODY WEIGHT AND WAIST CIRCUMFERENCE